Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The website has removed the 'Last Update Posted (Estimated)' and now features a definitive 'Last Update Posted' section.
    Difference
    0.0%
    Check dated 2024-07-24T18:26:49.000Z thumbnail image
  4. Check
    4 days ago
    Change Detected
    Summary
    New estimated update dates have been added for July 2024 and October 2025, while several previous update dates from early 2024 have been removed.
    Difference
    0.2%
    Check dated 2024-07-23T16:49:02.000Z thumbnail image
  5. Check
    5 days ago
    Change Detected
    Summary
    The study has expanded to include 179 locations, and the website has been updated to version v2.10.0, replacing the previous version v2.9.7.
    Difference
    0.1%
    Check dated 2024-07-22T14:49:32.000Z thumbnail image
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.0%
    Check dated 2024-07-16T10:08:10.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.
    Difference
    0.0%
    Check dated 2024-07-02T17:31:38.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent change in the version of the study record.
    Difference
    0.0%
    Check dated 2024-06-27T12:36:47.000Z thumbnail image

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.